Disease · HP_0000989

Comparisons in its trials41

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

1 to 20 of 41

Download this page as JSON

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Serlopitant 5 mg vs Placebo: deaths from any cause	1 of 147	0 of 148	295	NCT03677401	Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events	5 of 147	2 of 148	295	NCT03677401	Trial comparisons
Serlopitant 5 mg vs Placebo: deaths from any cause	0 of 139	0 of 141	280	NCT03546816	Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events	6 of 139	3 of 141	280	NCT03546816	Trial comparisons
Test Drug vs Control: Number of Patients Who Needed to Return to Treatment Center	7 of 127	19 of 135	262	NCT02935699	Trial comparisons
Test Drug vs Control: deaths from any cause	0 of 127	0 of 135	262	NCT02935699	Trial comparisons
Test Drug vs Control: serious adverse events	0 of 127	1 of 135	262	NCT02935699	Trial comparisons
Difelikefalin/Difelikefalin vs Placebo/Difelikefalin: Number of Participants With Clinically Relevant Change From Baseline in Vital Signs and Laboratory Evaluations	0 of 129	0 of 130	259	NCT05885737	Trial comparisons
Serlopitant 5 mg vs Placebo: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10	44 of 116	46 of 117	233	NCT03841331	Trial comparisons
Serlopitant 5 mg vs Placebo: deaths from any cause	0 of 116	0 of 117	233	NCT03841331	Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events	2 of 116	0 of 117	233	NCT03841331	Trial comparisons
Serlopitant 5 mg vs Placebo: deaths from any cause	0 of 102	1 of 100	202	NCT03343639	Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events	0 of 102	2 of 100	202	NCT03343639	Trial comparisons
Seladelpar vs Placebo: deaths from any cause	0 of 128	0 of 65	193	NCT04620733	Trial comparisons
Seladelpar vs Placebo: serious adverse events	9 of 128	4 of 65	193	NCT04620733	Trial comparisons
Tradipitant vs Placebo: deaths from any cause	0 of 83	0 of 82	165	NCT02651714	Trial comparisons
Tradipitant vs Placebo: serious adverse events	0 of 83	0 of 82	165	NCT02651714	Trial comparisons
Elafibranor 80 mg vs Placebo: deaths from any cause	2 of 108	0 of 53	161	NCT04526665	Trial comparisons
Elafibranor 80 mg vs Placebo: serious adverse events	11 of 108	7 of 53	161	NCT04526665	Trial comparisons
Intrathecal Hydromorphone vs Intrathecal Morphine: Nausea	28 of 66	32 of 68	134	NCT02789410	Trial comparisons

diseases-2026-09-18-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000989/comparisons

API reference For AI assistants

Comparisons in its trials41

Sources 6

Read this list from software.